What is the optimal antiplatelet therapy in patients with chronic coronary syndrome undergoing coronary artery bypass grafting?
J Cardiothorac Surg. 2026 May 6. doi: 10.1186/s13019-026-04256-w. Online ahead of print.ABSTRACTOBJECTIVE: Patients with chronic coronary syndrome (CCS) make up a large portion of those undergoing coronary artery bypass grafting (CABG), and there are significant gaps in the evidence regarding the op

